PT1919883E - N-óxidos como pró-medicamentos de derivados de piperazina & piperidina - Google Patents

N-óxidos como pró-medicamentos de derivados de piperazina & piperidina Download PDF

Info

Publication number
PT1919883E
PT1919883E PT06778284T PT06778284T PT1919883E PT 1919883 E PT1919883 E PT 1919883E PT 06778284 T PT06778284 T PT 06778284T PT 06778284 T PT06778284 T PT 06778284T PT 1919883 E PT1919883 E PT 1919883E
Authority
PT
Portugal
Prior art keywords
art
relates
disease
manufacture
disclosed
Prior art date
Application number
PT06778284T
Other languages
English (en)
Inventor
Roelof W Feenstra
Andrew C Mccreary
Mayke B Hesselink
Theodorus S M Koopman
Hendrik J Koster
Peter H Van Amsterdam
Marinus Verhage
Gustaaf J M Van Scharrenburg
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of PT1919883E publication Critical patent/PT1919883E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT06778284T 2005-08-22 2006-08-21 N-óxidos como pró-medicamentos de derivados de piperazina & piperidina PT1919883E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70982105P 2005-08-22 2005-08-22
EP05107671 2005-08-22

Publications (1)

Publication Number Publication Date
PT1919883E true PT1919883E (pt) 2009-03-26

Family

ID=39246895

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06778284T PT1919883E (pt) 2005-08-22 2006-08-21 N-óxidos como pró-medicamentos de derivados de piperazina & piperidina

Country Status (17)

Country Link
EP (1) EP1919883B1 (pt)
JP (1) JP2009504799A (pt)
KR (1) KR20080046205A (pt)
AT (1) ATE417834T1 (pt)
AU (1) AU2006283882B2 (pt)
CA (1) CA2621158A1 (pt)
DE (1) DE602006004363D1 (pt)
DK (1) DK1919883T3 (pt)
ES (1) ES2318783T3 (pt)
HR (1) HRP20090143T3 (pt)
IL (1) IL188903A0 (pt)
NO (1) NO20081435L (pt)
PL (1) PL1919883T3 (pt)
PT (1) PT1919883E (pt)
RU (1) RU2394821C2 (pt)
SI (1) SI1919883T1 (pt)
WO (1) WO2007023141A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
CA2654719A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising slv308 and a l-dopa
KR20090063228A (ko) 2006-08-31 2009-06-17 솔베이 파마슈티칼스 비. 브이 정신분열증 치료용 비페프루녹스를 위한 적정 계획 및 이에사용하기 위한 키트
EP2146961B1 (en) * 2007-04-12 2014-01-29 IVAX International GmbH N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
EP2234990A1 (en) * 2008-01-15 2010-10-06 Abbott Healthcare Products B.V. Bifeprunox derivatives
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
CA2869145A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE503170A (pt) * 1975-09-02
ATE340173T1 (de) * 1996-03-29 2006-10-15 Duphar Int Res Piperazin- und piperidin- derivate
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
DZ3370A1 (fr) * 2000-05-12 2001-11-15 Solvay Pharm Bv Composes de piperazine et piperidine
AU2003206722B2 (en) * 2002-01-16 2008-01-24 Mercury Pharma Group Limited Prucalopride-N-oxide

Also Published As

Publication number Publication date
CA2621158A1 (en) 2007-03-01
JP2009504799A (ja) 2009-02-05
EP1919883B1 (en) 2008-12-17
IL188903A0 (en) 2008-04-13
NO20081435L (no) 2008-05-16
KR20080046205A (ko) 2008-05-26
HRP20090143T3 (en) 2009-04-30
DE602006004363D1 (de) 2009-01-29
ES2318783T3 (es) 2009-05-01
RU2394821C2 (ru) 2010-07-20
RU2008110945A (ru) 2009-09-27
SI1919883T1 (sl) 2009-04-30
AU2006283882A1 (en) 2007-03-01
PL1919883T3 (pl) 2009-06-30
AU2006283882B2 (en) 2011-06-23
WO2007023141A1 (en) 2007-03-01
DK1919883T3 (da) 2009-04-14
ATE417834T1 (de) 2009-01-15
EP1919883A1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
HRP20090143T3 (en) N-oxides as prodrugs of piperazine&piperidine derivatives
TW200505907A (en) Piperidine-benzenesulfonamide derivatives
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
NZ537341A (en) Quinuclidine amide derivatives as antimuscarinic agents to treat respiratory disorders
ATE493407T1 (de) 3-(heteroaryloxy)-2-alkyl-1- azabicycloalkylderivate als alpha.7-nachr- liganden zur behandlung von zns-erkrankungen
WO2005079802A8 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
ES2162257T3 (es) N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina.
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
DE602004005502D1 (de) Comt-inhibitoren
NO20072972L (no) Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
ZA200906573B (en) Dibenzo[1,4]oxazapine compounds
UA94718C2 (ru) N-оксиды в качестве пролекарств производных пиперазина и пиперидина
UA96756C2 (en) N-oxides of pyridylmethylpiperazine and -piperidine derivatives
ATE334980T1 (de) Verfahren zur herstellung von 2-methyl piperazine derivaten.
BRPI0514077A (pt) derivados de benzilóxi como inibidores de maob
IL188109A0 (en) Chloro-substituted guanidines
MXPA06000193A (es) Derivados de imidazol iii.
DE69906728D1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen
DE502004010108D1 (de) Carbonylamino-substituierte acyl-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
TH91553A (th) N-ออกไซด์ที่เป็นโพรดรักส์ของอนุพันธ์พิเพอราซีนและพิเพอริดีน